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Abstract 
Objectives This study aimed to: 1) compare the amounts of growth factors from platelet-rich fibrin (PRF) between 
chronic periodontitis and periodontally healthy subjects; and 2) evaluate the relationships between the amounts of 
growth factors from PRF with complete blood counts (white blood cell (WBC) and platelet counts) and the serum 
concentrations of IL-1β, IL-6, and TNF-α. 
Materials and methods Venous blood was collected from chronic periodontitis (test) and periodontally healthy 
subjects (control). PRF and serum were collected from the centrifuged blood. Liquid exudates from the compression 
of PRF were collected. The compressed PRF membranes were incubated in saline and eluted aliquots were collected 
at 1, 24, and 72 hours, and the membranes were then digested with trypsin. EGF, IGF-1, PDGF-BB, TGF-β1, and 
VEGF in the exudates and eluents were quantified by ELISA. Serum was used for IL-1β, IL-6, and TNF-α 
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quantification. Complete blood counts were measured. 
Results There were no significant differences in the amounts of growth factors from PRF exudates and membranes 
measured between groups (all p>0.05). The test group had significantly higher WBC (p<0.05). However, there was 
no significant correlation between the WBC and the amounts of the growth factors from PRF (all p>0.05).  
Conclusions PRF can be utilized as an autologous source of growth factors not affected by periodontal condition and 
WBC level. 
Clinical relevance The amounts of growth factors from PRF were not affected by the periodontal condition of the 
patient. 
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Introduction:   
The most recent National Health and Nutrition Examination Survey estimates that 47.2% of the U.S. population 
between the ages of 30 to 70 years old are affected by periodontitis [1]. Periodontitis is a microbial biofilm-induced 
inflammatory disease, causing periodontal tissue destruction and eventual tooth loss. The inflammatory status of 
periodontitis is associated with systemic elevation of pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-
6, and tumor necrosis factor-α (TNF-α) [2]. Current treatment regimens utilize a variety of techniques and materials 
attempting to regenerate soft and hard tissues around the teeth and the resultant alveolar ridge defects from 
destructive periodontal disease [3, 4]. 
Platelet-rich fibrin (PRF) is categorized as a second-generation platelet concentrate, which is collected from 
centrifuged blood of patients without the use of any anticoagulants resulting in initiation of the natural coagulation 
cascade by platelets with fibrinogen being transformed by thrombin into fibrin. After centrifugation, the fibrin clot is 
obtained between the erythrocytes at the bottom and the acellular serum at the top due to density differences. 
Platelets entrapped within the fibrin clot release growth factors upon activation and degranulation [5-9]. Results 
from previous studies revealed that autologous blood concentrates are a safe and convenient source to deliver 
polypeptide growth factors such as epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), platelet-
derived growth factor-BB (PDGF-BB), transforming growth factor-β1 (TGF-β1), and vascular endothelial growth 
factor (VEGF) [10, 11]; all of which can enhance wound healing and periodontal regeneration. The advantages of 
utilizing PRF as an autologous source of growth factors compared to other allograft or xenograft sources are that 
concerns of disease transmission and adverse immunogenic reactions are eliminated. Numerous studies have 
evaluated the benefits of clinical application of PRF for periodontal regenerative therapies and reported 
improvements in clinical periodontal parameters and the enhanced healing of soft and hard tissues [12-14].  
As an autologous material, patient-related factors may affect the quantity and quality of the PRF. For example, 
previous study demonstrated that older and female patients could produce larger PRF membranes [15]. However, 
very few studies have been done evaluating patient-related factors affecting the quantity and types of growth factors 
from PRF. There is no available information to determine if the platelet count or the inflammatory status of patients 
with chronic periodontitis may influence the levels of growth factors present and released over time from the PRF. 
Platelets are the source of many of the known growth factors released from PRF [16]. Furthermore, previous studies 
have demonstrated several possible links of periodontitis to systemic diseases with evidence of systemic 
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inflammatory responses which could either activate platelets to release growth factors [17], or possibly with 
inflammation, healing response may be down regulated, with decreased amounts of growth factors from PRF. 
Therefore, the objectives of this study were to: 1) compare the amounts of growth factors (EGF, IGF-1, PDGF-BB, 
TGF-β1, and VEGF) from PRF between chronic periodontitis and periodontally healthy subjects; and 2) evaluate the 
relationship between the amounts of growth factors from PRF with the complete blood count (white blood cell and 
platelet counts) and the concentrations of IL-1β, IL-6, and TNF-α. 
Materials and Methods: 
Subjects: 
All subjects were recruited from the Graduate Periodontics Clinic and the Comprehensive Care Clinics of Indiana 
University School of Dentistry with approval from the Indiana University Institutional Review Board (protocol# 
1704165172) between September to November 2017.  Subjects were screened to confirm that they met the inclusion 
criteria and written informed consents were obtained. The study group were patients with a diagnosis of generalized 
moderate to severe chronic periodontitis. Based on the 2015 American Academy of Periodontology Task Force 
report on the update to the 1999 classification [18], patients with greater than 30% of teeth presented with bleeding 
on probing, clinical attachment loss of 3 to 4mm, probing depth ≥5 and <7mm, and radiographic bone loss 16 to 
30% were classified as generalized moderate chronic periodontitis. In addition, patients with greater than 30% of 
teeth presented with bleeding on probing, clinical attachment loss of ≥5mm, probing depth ≥7mm, and radiographic 
bone loss >30% were classified as generalized severe chronic periodontitis. The control group were subjects without 
periodontitis. The inclusion criteria of subjects were between the ages of 30 to 65, controlled or no systemic 
diseases, and non-smokers. The exclusion criteria were: 1) uncontrolled systemic diseases, such as uncontrolled 
diabetes (HbA1c≥6.5%) and uncontrolled hypertension; 2) recent history of myocardial infarction, cerebrovascular 
accident, transient ischemic attack, or coronary artery disease diagnosed in the past 6 months; 3) immuno-
compromised diseases; 4) BMI<18.5 or ≥40 kg/m2; 5) pregnancy; 6) smokers; 7) receiving chemotherapy, 
radiotherapy, corticosteroid, anticoagulant, antiplatelet or nonsteroidal anti-inflammatory drugs; 8) antibiotic therapy 
within 6 months; 9) history of drug or substance abuse; or 10) patients received surgical or nonsurgical periodontal 




Intravenous access was obtained through the cubital region of the arm or dorsum of the hand for blood collection 
based on vessel size and accessibility. A total of 13 ml of whole blood were collected from each subject. Three ml 
were sent to the Indiana University Health Pathology Lab for complete blood count (CBC) analysis. The remaining 
10 ml were centrifuged (Kendro Laboratory Products, Hanau, Germany) at 2700 rpm (relative centrifuge force max 
was about 650 g) for 12 minutes for PRF and serum collection. The collected sera were frozen at -80°C for later pro-
inflammatory cytokine (IL-1β, IL-6, and TNF-α) quantification by ELISA (R&D Systems, MN, USA). After 
centrifugation, the PRF clots were harvested and compressed for 5 minutes in a PRF box (OSUNG MND Co, 
Kyonggi-do, Korea) into flattened PRF membranes. Membranes were trimmed into a uniform dimension of 15 x 20 
mm2 from each PRF clot and weighed (Fisher Scientific Company, MA, USA) for standardization. The 15 x 20 mm2 
membranes and the liquid exudates from the compressed PRF were frozen at -80°C for later growth factor 
quantification. The samples were stored at -80°C to minimize possible degradation of both the cells and the growth 
factor proteins of the PRF as much as possible. To avoid possible degradation of the proteins, the samples were 
stored no longer than 3 months before measurement. 
Growth factor quantification by ELISA: 
After collection of the samples, the 15 x 20 mm2 membranes were incubated at 37°C in 5 ml of saline, and at 1, 24, 
and 72 hours, eluted aliquots (1.6 ml) were collected and frozen at -80°C until analyzed. After 72 hours of 
incubation, the remaining membranes were digested to determine the amount of residual/unreleased growth factors 
from the membranes with 10 µg/mL trypsin (Worthington Biochemical Corporation, NJ, USA) for 24 hours. After 
trypsin digestion, 1 mg/mL soybean trypsin inhibitor (Worthington Biochemical Corporation, NJ, USA) was added 
to inhibit the trypsin. The PRF liquid exudates, the aliquots from PRF membrane incubation, and the digested 
membranes were analyzed by ELISA (R&D Systems, MN, USA) according to the manufacturer’s instructions for 
EGF, IGF-1, PDGF-BB, TGF-β1, and VEGF detection and quantification.  
Sample size calculation and statistical analysis: 
Sample size calculation was done based on previous growth factors measurements from PRF by Kobayashi et al. 
[19], the standard deviations for the total growth factor release over 3 days are 235 pg/mL for TGF, 63 pg/mL for 
VEGF, 95 pg/mL for EGF, 33 pg/mL for IGF, and 155 pg/mL for PDGF-BB. With a sample size of 8 subjects per 
group, the study will have 80% power to detect TGF differences between groups of 354 pg/mL for TGF, 95 pg/mL 
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for VEGF, 143 pg/mL for EGF, 50 pg/mL for IGF, and 234 pg/mL for PDGF-BB, assuming two-sided tests 
conducted at a 5% significance level.  
Comparison of the effects of group and time on the growth factor measurements and the differences in growth 
factors present and released from membranes and exudates were made using repeated measures ANOVA. 
Comparisons between the test and control groups for differences in CBC and pro-inflammatory cytokine 
measurements were made using two-sample t-tests. Pearson correlation coefficients were calculated to assess the 
associations of the growth factor measurements with WBC counts, platelet counts, and pro-inflammatory cytokine 
concentrations. Correlation coefficients were compared between test and control groups using a z-test. A 5% 




Ten subjects in the test group and nine in the control group were enrolled in the study (the demographic data of the 
groups are listed in Table 1). One subject from the test group and two from the control group were excluded from 
CBC analysis due to coagulation of the blood samples sent for analysis. Quantification of growth factors from the 
PRF were completed on all 19 subjects. The subjects were age matched and there was no statistically significant 
difference of mean age between groups (test 52.2 ± 3.6 years and control 52.8 ± 9.2 years, p = 0.901). 
Growth factors from exudates and membranes between the groups: 
Results of growth factor levels from exudates and membranes are listed in Figure 1 and Table 2. There were no 
significant differences for EGF (p = 0.10), IGF-1 (p = 0.83), PDGF-BB (p = 0.11), TGF-β1 (p = 0.83), and VEGF (p 
= 0.36) measured from the exudates between the test and control groups. Also, there were no significant differences 
for EGF (p = 0.19), IGF-1 (p = 0.09), PDGF-BB (p = 0.56), TGF-β1 (p = 0.81), and VEGF (p = 0.38) measured 
from the membranes between the test and control groups. Overall, there were no significant differences for EGF (p = 
0.22), IGF-1 (p = 0.42), PDGF-BB (p = 0.44), TGF-β1 (p = 0.85), and VEGF (p = 0.34) measured from the entire L-
PRF clots between the test and control groups. For EGF, PDGF-BB, TGF-β1, and VEGF, the membranes contained 
significantly more growth factors than the exudates (p < 0.01). However, for IGF-1 there were no significant 
differences measured from the exudates or the membranes of both the test and control groups (p = 0.52 for the test 
group and p = 0.33 for the control group). 
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Growth factors released over time between the groups:  
EGF: 
Results of growth factors released over time are listed in Figure 2 and Table 3. Both test and control groups 
exhibited significantly lower EGF amounts released after 1 hour of incubation compared to 24 and 72 hours (p < 
0.05). Comparing the EGF being released from the membranes to that being entrapped within the remaining 
membranes (residual EGF), the majority of the EGF was released within 72 hours for both groups (p < 0.05). The 
control group had significantly higher amounts of EGF release when measured after 1 hour of membrane incubation 
than the test group (p = 0.00). In addition, the control group had significantly more residual EGF entrapped in the 
membranes than the test group (p = 0.04). 
IGF-1: 
The control group had significantly higher amounts of IGF-1 release than the test group when measured after 1 hour 
of membrane incubation (p = 0.04). Compared to 24 and 72 hours, the control exhibited the highest IGF-1 amount of 
release after 1 hour of incubation (p < 0.05). For the test group, IGF-1 release at 24 hours was higher than 72 hours 
(p < 0.05). For both the test and control groups, there were significantly greater amounts of released IGF-1 
compared to membrane-retained IGF-1 (p < 0.05). 
PDGF-BB: 
Compared to 1 hour, both groups exhibited higher amount of PDGF-BB released after 24 and 72 hours of incubation 
(p < 0.05). Comparing the PDGF-BB released from the membranes to that remaining entrapped within the 
remaining membranes, the majority of the growth factor was released for both groups (p < 0.05). No significant 
differences were found comparing PDGF-BB measurements at 1, 24, 72 hours, and entrapped within the membranes 
between the test and the control groups (p > 0.05). 
TGF-β1: 
The test group had a significantly higher amount of TGF-β1 released when measured after 1 hour of membrane 
incubation (p = 0.04). Compared to 1 hour, both groups exhibited higher amounts of TGF-β1 released after 24 and 
72 hours of incubation (p < 0.05). Comparing the amount of TGF-β1 released from the membranes to that entrapped 
within the remaining membranes, the majority of the growth factor was released for both groups within 72 hours (p 
< 0.05). No significant differences were found comparing TGF-β1 measurements at 1, 24, 72 hours, and entrapped 




For both the test and the control groups, the VEGF amount released at 24 and 72 hours was significantly higher than 
1 hour (p < 0.05). Comparing the amount of VEGF released from the membranes to that entrapped within the 
remaining membranes, the majority of the growth factor was released for both groups (p < 0.05). No significant 
differences were found comparing VEGF measurements at 1, 24, 72 hours, and entrapped within the membranes 
between the test and the control groups (p > 0.05). 
Comparison of CBC and pro-inflammatory cytokines between the groups: 
The test group had significantly higher WBC counts than the control group (p = 0.04), but no other statistically 
significant group differences were found among the CBC results, including the platelet count (p = 0.33). However, 
there were no significant correlations of the growth factors studied with the WBC counts for both test and control 
subjects (p > 0.05). In addition, no statistically significant group differences were found when comparing the 
amount of IL-1β (p = 0.93), IL-6 (p = 0.62), and TNF-α (p = 0.29) between the test and the control groups (Table 4).  
 
Discussion: 
The results from the current study revealed that the amounts of growth factors (EGF, IGF-1, PDGF-BB, TGF-β1, 
and VEGF) present in the liquid exudates and released from the PRF membranes had wide range of values between 
individuals, but there were no significant differences between the test and the control groups. This suggests that the 
amounts of growth factors studied were not affected by the periodontal disease status of the subjects.  
Also, except for IGF-1, there were much higher concentrations of EGF, PDGF-BB, TGF- β1, and VEGF in the PRF 
membranes compared to the exudates. Such findings support the clinical use of PRF membranes as an autologous 
growth factor delivery vehicle. However, since growth factors were still detected in the PRF exudates, and the IGF-1 
amounts from the exudates was comparable to that from the membranes, hydrating graft materials with PRF 
exudates in combination with utilizing the PRF membranes can maximize the benefits from the entire PRF clot. 
Furthermore, relative to the release of growth factors from the PRF membranes, IGF-1 tended to be released almost 
immediately, while the amounts of EGF, PDGF-BB, TGF- β1, and VEGF were mostly released within the first 24 
hours that reached plateaus. Very little additional growth factor release by 72 hours was observed that could be due 
to either the plateau was reached or the nature of our study design that the PRF membranes were digested by trypsin 
at the end of the study. There were occasional instances when the total growth factor released at later time periods 
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was less than previous time periods (Table 3). This may have been due to the fact that the majority of the growth 
factors were released and no more were available. Additionally, there were still small amounts of growth factors that 
remained entrapped in the remaining membranes at 72 hours. Although it was found that the majority of the growth 
factors were released within the first 24 hours, the entrapped growth factors still detected after 72 hours of 
incubation may support the clinical application of PRF membranes where some growth factors may be still released 
over an extended period at the surgical site until eventual fibrinolysis of the membranes. The present study used 
saline to incubate the samples. Although culture media can ensure viability of cells, the growth factors measured are 
released from platelets rather than the trapped leukocytes [16]. Cell viability would not be expected to have an effect 
on the amounts of measured growth factors, but further study is warranted to verify this. The results revealed that the 
control group had significantly higher amounts of EGF release when measured at 1 hour after membrane incubation 
(p = 0.00) and significantly more residual EGF entrapped in the membranes than the test group (p = 0.04). 
Furthermore, there were significantly greater amounts of IGF-1 released at 1 hour by the control group, compared to 
the test group (p = 0.04). Since EGF and IGF-1 regulates cell differentiation and proliferation in wound healing [16], 
the wound healing capacity from patients with active inflammation from chronic periodontitis may be down-
regulated. However, the results demonstrated that the test group had significantly higher amounts of TGF-β1 release 
at 1 hour from the PRF membranes (p = 0.04). The initial elevation of TGF-β1 may be partially explained, as TGF-
β1 promotes inflammatory cell recruitment and inflammation increases TGF-β1 response [16, 20]. 
Although the results exhibited higher WBC levels in the test group, there were no correlations found between the 
WBC numbers and the amounts of the growth factors between the groups. Possible explanation of such observation 
could be that with the present PRF preparation protocol, WBC are less entrapped within the PRF compared to other 
centrifuge protocols which tubes of blood are centrifuged at a slower speed [21]. Furthermore, as the subjects in the 
test group were patients with untreated generalized moderate to severe chronic periodontitis, the inflammatory status 
represented by elevated leukocytes was expected [22]. While no other differences were found from the results of the 
CBC analysis between groups, this might be expected as all subjects were systemically healthy or had controlled 
systemic diseases. Even though a previous study by Gorska et al. revealed elevation of pro-inflammatory cytokines 
with periodontitis, they found higher cytokine concentrations in gingival crevicular fluid compared to the systemic 
circulation [2]. In the present study, the amount of pro-inflammatory cytokines of the subjects at a systemic level 
were determined by the collected serum from the centrifuged blood. As chronic periodontitis primarily causes 
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inflammation of the periodontium, it is understandable that systemic inflammatory responses may not reflect those 
found at the local level. 
There are several PRF preparation protocols. The PRF centrifugation protocol used in the present study has been 
reported to entrap leukocytes and platelets within the fibrin clot [23]. However, the source of EGF, IGF-1, PDGF-
BB, TGF-β1, and VEGF are primarily from the platelets rather than the leukocytes [16]. Therefore, it is not 
surprising to find that there were no correlations between the WBC and the amounts of growth factors from PRF. 
No previous research could be found that evaluated the influence of CBC or chronic periodontitis status on the 
quantity or release of growth factors from PRF. Kobayashi et al. evaluated the comparative release of growth factors 
from PRF, advanced-PRF, and platelet-rich plasma from healthy individuals. They quantified the amounts and 
release of growth factors including PDGF-AA, PDGF-AB, PDGF-BB, TGF-β, VEGF, EGF, and IGF released from 
platelet concentrates by ELISA for up to 10 days. The amounts of growth factors quantified are similar to the results 
of the present study, while large standard deviations were found for both studies. The authors suggested that several 
patient-related factors might affect growth factor release, so that there may be a wide variability of the amounts of 
growth factors released. Although the results of the current study were similar to that of the Kobayashi study, direct 
comparisons should be avoided as the study methods were not the same. Kobayashi et al. evaluated growth factors 
from PRF clots, while the present study used compressed PRF membranes as PRF is commonly used in the 
membranous form [24, 25]. The current study also digested the remaining membranes to quantify the amount of 
growth factors not released and remaining entrapped within the fibrin clots.  
The strengths of the current study design were that after separation of the liquid exudates from the PRF membranes, 
comparisons of growth factors from membranes and exudates were possible. Also, digestion of the remaining 
membranes with trypsin after incubation to quantify the growth factors entrapped in the remaining fibrin clot which 
may reflect contained growth factor release during the clinical degradation of the PRF membranes.  
In conclusion, the amounts of growth factors released from PRF show variation between patients. However, the 
amounts of growth factors from the PRF exudates or the PRF membranes had no statistically significant differences 
between the test and the control groups. Except IGF-1, most of the growth factors were from the membranes rather 
than the exudates. The majority of the growth factors were released within 24 hours of incubation and the small 
remaining amounts of growth factors continued to be released up to 72 hours. The low levels of residual growth 
factors noted after 72 hours suggests a continued release until eventual fibrinolysis of the PRF membranes occurs. 
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CBC results indicated that the test group had significantly higher WBC (p < 0.05). However, there was no 
significant correlation between the WBC counts and the amounts of any of the tested growth factors from PRF. 
Within the limitations of the current study, one can conclude that PRF can be utilized as an autologous source of 
growth factors not affected by periodontal condition and the numbers of WBC of the healthy patients. Large 
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Table 1. Demographic data of the subjects 
Groups Mean age  
(year ± SD) 
Patient # Age Gender 
Test (n=9) 52.2±10.8 1 65 Male 
2 60 Male 
3 41 Female 
4 34 Male 
5 61 Male 
6 54 Male 
7 48 Male 
8 62 Female 
9 63 Female 
Control 
(n=10) 
52.8±9.2 A 60 Female 
B 64 Female 
C 51 Female 
D 37 Male 
E 56 Female 
F 54 Female 
G 55 Male 
H 62 Male 
I 39 Male 










Table 2. Growth factor measurements from PRF liquid exudates compressed from PRF, PRF membranes, 
and the combination of both between the groups at the end of the study 
 Median (Q1-Q3)  
(pg/PRF) 
Growth factor Control group Test group P value 
EGF (E) 42.39 (33.67-117.87) 94.96 (55.09-128.29) 0.10 
EGF (M) 2437.15 (2155.65-2762.52)* 1846.43 (1704.14-1976.76)* 0.19 
IGF-1 (E) 76901.57 (54503.36-103687.75) 89387.58 (55075.50-102111.30) 0.83 
IGF-1 (M) 78782.92 (69528.38-97154.04) 63111.30 (49633.97-73039.87) 0.09 
PDGF-BB (E) 492.31 (227.59-731.78) 959.82 (779.09-1035.78) 0.11 
PDGF-BB (M) 3457.91 (1919.87-4503.78)* 3792.63 (3254.03-4887.49)* 0.56 
TGF-β1 (E) 953.12 (536.52-1449.39) 1034.42 (913.33-1334.61) 0.83 
TGF-β1 (M) 7859.79 (7252.62-9463.45)* 6896.36 (6076.73-7962.62)* 0.81 
VEGF (E) 169.11 (103.29-214.56) 95.80 (54.61-132.00) 0.36 
VEGF (M) 1008.92 (699.31-1158.00)* 532.96 (433.19-1196.11)* 0.38 
Q1: 25 percentile, Q3: 75 percentile, (E): PRF exudates, (M): PRF membranes. 
* Growth factors from the membranes were significantly higher than the exudates for EGF, PDGF-BB, TGF- β1, and 














Table 3. Growth factors released over time between the groups 
 Median (Q1-Q3)  
(pg/PRF) 
Growth factor  
(Elution time-hours) 
Control group Test group P value 
EGF (1) 828.87 (636.64-1101.70)** 149.87 (15.39-410.66)** 0.00* 
EGF (24) 1691.04 (1182.46-2373.72) 1519.14 (1262.39-1819.70) 0.89 
EGF (72) 1703.15 (1135.13-2150.89) 1428.66 (1386.88-1693.82) 0.61 
EGF (Remaining) 486.43 (404.85-737.94)# 310.03 (275.48-406.64)# 0.04* 
IGF-1 (1) 6782.95 (45442.62-71561.27) 38527.51 (29429.39-42807.63) 0.04* 
IGF-1 (24) 47102.49 (41699.75-63322.27)** 41727.26 (30805.39-46692.09) 0.11 
IGF-1 (72) 50405.00 (38485.60-54728.60)** 36757.76 (32300.42-45706.78)** 0.06 
IGF-1 (Remaining) 35492.03 (23239.62-41824.78)# 23083.58 (18096.36-37868.89)# 0.36 
PDGF-BB (1) 323.64 (240.00-522.96)** 731.76 (270.66-1647.11)** 0.11 
PDGF-BB (24) 2558.51 (1604.59-4313.83) 2706.48 (2475.05-3688.59) 0.69 
PDGF-BB (72) 3119.96 (1716.31-4327.78) 3680.12 (3172.33-4805.51) 0.50 
PDGF-BB (Remaining) 282.98 (187.94-415.23)# 288.63 (112.50-408.99)# 0.53 
TGF-β1 (1) 893.04 (581.26-1093.58)** 1684.36 (651.15-2644.86)** 0.041 
TGF-β1 (24) 6477.30 (5264.97-7594.26) 5309.62 (4356.53-5446.23) 0.75 
TGF-β1 (72) 6936.05 (6289.64-7167.02) 5963.16 (4822.08-6566.78) 0.64 
TGF-β1 (Remaining) 1201.81 (459.26-2443.42)# 1104.49 (627.08-2167.80)# 0.86 
VEGF (1) 123.14 (82.37-217.75)** 95.38 (79.37-200.00)** 0.69 
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VEGF (24) 712.16 (431.14-823.81) 346.31 (315.22-723.64) 0.36 
VEGF (72) 700.17 (458.40-753.43) 326.83 (298.62-756.75) 0.44 
VEGF (Remaining) 288.50 (136.27-294.85)# 253.91 (134.56-279.60)# 0.49 
Q1: 25 percentile, Q3: 75 percentile, (1): Growth factors released detected at 1 hour, (24): growth factors released 
detected at 24 hours, (72): Growth factors released detected at 72 hours, (Remaining): growth factors remaining 
entrapped within the PRF membranes. 
 
* P value < 0.05: Significant differences between the test and control groups. (P value calculated based on means and 
standard errors between groups.) 
** Significantly lower within the test and control groups (p < 0.05). 





























Table 4. CBC and pro-inflammatory cytokines between the groups 
 Median (Q1-Q3) 
 Control group Test group P value 
WBC (cells/mm3) 5.60 (5.25-6.55) 7.80 (6.38-8.78) 0.04* 
Platelet (cells/mm3) 232.00 (216.00-257.75) 242.50 (160.75-288.00) 0.38 
IL-1β (pg/mL) 3.88 (2.69-5.25) 4.42 (2.94-4.78) 0.93 
IL-6 (pg/mL) 1.48 (0.82-2.98) 3.99 (3.78-10.06) 0.62 
TNF-α (pg/mL) 7.98 (4.16-14.62) 11.82 (11.18-14.92) 0.29 
Q1: 25 percentile, Q3: 75 percentile. 
* The test group had significantly higher WBC than the control group (p < 0.05, calculated based on means and 























Figure 1. Growth factor measurements from PRF liquid exudates, PRF membranes, and the combination of 
both between the groups at the end of the study 
*Growth factors from the PRF membranes were significantly higher than the exudates (p < 0.01). 
 
Figure 2. Growth factors released from PRF membranes over time between the groups 
* Both test and control groups exhibited significantly lower EGF amounts released after 1 hour of incubation 
compared to 24 and 72 hours (p < 0.05). 
+ The majority of the EGF was released within 72 hours for both groups (p < 0.05).  
! The control group had significantly higher amounts of EGF release when measured after 1 hour of membrane 
incubation and more residual EGF entrapped in the membranes than the test group (p < 0.05). 
@ The control group had significantly higher amounts of IGF-1 release than the test group when measured after 1 
hour of membrane incubation and exhibited the highest IGF-1 amount of release after 1 hour of incubation (p < 
0.05).  
# For the test group, IGF-1 release at 24 hours was higher than 72 hours (p < 0.05).  
$ For both the test and control groups, there were significantly greater amounts of released IGF-1 compared to 
membrane-retained IGF-1 (p < 0.05). 
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% Compared to 1 hour, both groups exhibited higher amount of PDGF-BB, TGF- β1, and VEGF released after 24 
and 72 hours of incubation (p < 0.05).  
& Comparing the released from the membranes to that remaining entrapped within the remaining membranes, the 
majority of PDGF-BB, TGF- β1, and VEGF were released for both groups (p < 0.05).  
 
Figure 3. Comparison of CBC and pro-inflammatory cytokines between the groups 
*The test group had significantly higher WBC than the control group (p < 0.05). 
